Kymera Therapeutics (KYMR)
(Delayed Data from NSDQ)
$33.35 USD
-1.86 (-5.28%)
Updated Apr 25, 2024 04:00 PM ET
After-Market: $33.38 +0.03 (0.09%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth F Momentum F VGM
Price, Consensus and EPS Surprise
KYMR 33.35 -1.86(-5.28%)
Will KYMR be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for KYMR based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for KYMR
Kymera Therapeutics, Inc. (KYMR) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
Repare Therapeutics Inc. (RPTX) May Report Negative Earnings: Know the Trend Ahead of Q4 Release
KYMR: What are Zacks experts saying now?
Zacks Private Portfolio Services
Kymera Therapeutics, Inc. (KYMR) Expected to Beat Earnings Estimates: Should You Buy?
Merus N.V. (MRUS) Surges 16.3%: Is This an Indication of Further Gains?
Kymera (KYMR) Rises as Dosing Begins in AD Study on KT-474
Other News for KYMR
Kymera Therapeutics to Report First Quarter 2024 Financial Results on May 2
Commit To Buy Kymera Therapeutics At $17.50, Earn 9% Annualized Using Options
Cisco downgraded, Lucid resumed: Wall Street's top analyst calls
Kymera Therapeutics Stock: A Deep Dive Into Analyst Perspectives (5 Ratings)
Kymera Therapeutics initiated with bullish view at Oppenheimer, here's why